Jefferies upgraded Quest Diagnostics from Hold to Buy and set a new price target of $155.00 from $140.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2026 | $210.00 | Equal Weight → Overweight | Barclays |
| 8/25/2025 | $194.00 | Outperform → Neutral | Robert W. Baird |
| 4/2/2025 | $195.00 | Buy | Redburn Atlantic |
| 3/4/2025 | $185.00 | Buy → Neutral | Citigroup |
| 1/6/2025 | $169.00 → $174.00 | Market Perform → Outperform | Leerink Partners |
| 12/17/2024 | $145.00 → $172.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/10/2024 | $175.00 → $185.00 | Buy | Jefferies |
| 10/23/2024 | $157.00 → $182.00 | Neutral → Outperform | Robert W. Baird |
Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024 Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagno
SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's
New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting better care and outcomes.
Barclays upgraded Quest Diagnostics from Equal Weight to Overweight and set a new price target of $210.00
Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00
Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00
8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham
Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh
Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024 Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagno
SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's
SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)